"We are pleased that the PharmaJet device is being used for this important study, and are encouraged by the improved compliance that needle-free may provide. This is consistent with our survey data that shows 93% of patients would choose needle-free again for their next vaccination2," said Ron Lowy, Chairman and Chief Executive Officer, PharmaJet Inc. "Given that multiple vaccine doses are required for the HPV vaccine, improved compliance with needle-free is an important advantage."
To view Vaccibody's announcement click here. For more information about PharmaJet visit www.pharmajet.com.
Refer to Instructions for Use to ensure safe injections and to review risks.
1 Vaccibody announces positive results from the phase 1 part of the clinical trial, press release, Aug. 25, 2016. www.vaccibody.com/news
2 PharmaJet, Inc. (2014) 61-10201 Post Market Surveillance – internal company report, February, 2015.
Based in Golden, Colorado, PharmaJet's mission is worldwide acceptance of PharmaJet needle-free devices as a standard of care in the vaccine delivery market. PharmaJet's devices are also integral in the development of multiple novel pharmaceuticals. The innovative Stratis® Injector has U.S. FDA 510(k) marketing clearance, CE Mark and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. In August 2014, the PharmaJet Stratis® Needle-free Injector was cleared for delivery of an influenza vaccine to deliver needle-free flu shots. The PharmaJet Tropis® device for intradermal injections received authorization to apply the CE Mark in May 2016. The PharmaJet Needle-free Injectors are safe, fast and easy-to-use. They eliminate needlestick injuries, needle reuse and cross contamination, and help reduce sharps waste disposal. For more information, visit www.pharmajet.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pharmajet-and-vaccibody-collaborate-on-hpv-vaccine-development-300347191.html